Journal of Diabetes and Its Complications
Volume 23, Issue 3 , Pages 214-218 , May 2009

The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats

  • Yang Lin

      Affiliations

    • Department of Endocrinology, Anhui Provincial Hospital affiliated to Anhui Medical University, Hefei, 230001, China
    • ,
  • Shandong Ye

      Affiliations

    • Department of Endocrinology, Anhui Provincial Hospital affiliated to Anhui Medical University, Hefei, 230001, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 551 2283301; fax: +86 551 2283292.
    • ,
  • Yan Chen

      Affiliations

    • Endocrinological Laboratory of Anhui Provincial Hospital, Hefei, 230001, China
    • ,
  • Xiucai Li

      Affiliations

    • Department of Endocrinology, Anhui Provincial Hospital affiliated to Anhui Medical University, Hefei, 230001, China
    • ,
  • Guang-wei Yang

      Affiliations

    • Department of Endocrinology, Anhui Provincial Hospital affiliated to Anhui Medical University, Hefei, 230001, China
    • ,
  • Aihong Fan

      Affiliations

    • Endocrinological Laboratory of Anhui Provincial Hospital, Hefei, 230001, China
    • ,
  • Yingxin Wang

      Affiliations

    • Department of Pharmacology, Anhui Medical College, Hefei, China

Received 28 July 2007 ,Accepted 6 September 2007.

References 

  1. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068–2102
  2. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Ros RD, Maier A, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin in treatment. Diabetes. 2004;53:701–710
  3. DeGraba TJ, Siren AL, Penix L, McCarron RM, Hargraves R, Sood S, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke. 1998;29:1405–1410
  4. De Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–695
  5. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular. 2003;23:58–63
  6. Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, et al. Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovascular Diabetologica. 2006;5:1–9
  7. Han KH, Ryu J, Hong KH, Ko J, Pak YK, Kim JB, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005;111:1439–1447
  8. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. Journal of the American College of Cardiology. 1994;24:1591–1601
  9. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, et al. Evidence for anti-inflammatory activity of statins and PPAR-α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood. 2004;103:4188–4194
  10. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3687–3692
  11. Lee S, Kim B, Sik Y, Kim SB, Park SK, Park JS. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney International. 2001;60:55–64
  12. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta JL. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: Role of LOX-1. Pharmacology & Therapeutics. 2002;302:601–605
  13. März W, Köenig W. HMG-CoA reductase inhibition: Anti-inflammatory effects beyond lipid lowering?. Journal of Cardiovascular Risk. 2003;10:169–179
  14. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clinical and Experimental Immunology. 2000;121:437–443
  15. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Laboratory Investigation. 2000;80:1095–1100
  16. Sowers JR. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. American Journal of Cardiology. 2003;91:14B–22B
  17. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation. 2001;108:1429–1437
  18. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacology & Therapeutics. 2003;99:95–112
  19. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, et al. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. Journal of Clinical Investigation. 2005;115:2508–2516
  20. Zhu DL. The relationship between inflammation and type 2 diabetes. Chinese Journal of Investigative. 2006;14:73–74

PII: S1056-8727(07)00109-2

doi: 10.1016/j.jdiacomp.2007.09.003

Journal of Diabetes and Its Complications
Volume 23, Issue 3 , Pages 214-218 , May 2009

Article Tools

* Image Usage & Resolution